

# Children's Oncology Group

**The following guideline is no longer current and its recommendations may no longer be valid.  
This document is provided for historical purposes only.**

**ARCHIVED: August 2018**

## Supportive Care Guidelines

### Terms of Use, Disclaimer, and Notice of Copyright

The information and content provided in the *Children's Oncology Group Supportive Care Guidelines* is made available for informational purposes only for children and their families affected by cancer. While the Children's Oncology group strives to provide accurate and up-to-date information, the information may be out of date or incomplete in certain respects. This document may contain parts that are to be used by clinical researchers in a clinical setting. As such, users are advised that the information and guidelines may not conform to current standard of care, state-of-the art, or best practices for a particular disease, condition, or treatment. Please do not rely on this information exclusively and seek the care of a qualified medical professional if you have questions regarding a specific medical condition, disease, diagnosis or symptom. The information and content presented herein is not intended to replace the independent clinical judgment, medical advice, screening, health counseling, or other intervention performed by your (or your child's) healthcare provider. Please contact "911" or your emergency services if this is a health emergency. No endorsement of any specific tests, products, or procedures is made herein.

This document is provided to qualified members of the Children's Oncology Group (or their affiliates) who are in good standing and have agreed to collaborate with the Children's Oncology Group in accordance with the relevant procedures and policies for study conduct and membership participation. Requirements applicable to recipients of U.S. governmental funds may apply to the use and dissemination of this document or the information contained herein.

The Children's Oncology Group Supportive Care Guidelines is proprietary to the Children's Oncology Group (© 2007). The National Childhood Cancer Foundation may own, manage, and/or hold certain rights on behalf of and as an affiliated organization of the Children's Oncology Group. Unauthorized reproduction, dissemination, and/or use is prohibited and neither the Children's Oncology Group nor the National Childhood Cancer Foundation (nor the trustees, officers, employees, agents, representatives, or members of each thereof) shall be responsible or liable for any resulting injury, harm, or other damage of unauthorized reproduction, dissemination, and/or use. You, as user, agree to indemnify the National Childhood Cancer Foundation and/or the Children's Oncology Group (and the trustees, officers, employees, agents, representatives, and/or members of each organization) for any cost and/or claim resulting from the injury, harm, or other damage caused by your unauthorized or prohibited use (and related acts) as described in the foregoing sentence, to the maximum extent permissible under law. Individuals are encouraged to contact the Children's Oncology Group for questions or comments concerning the Children's Oncology Group Supportive Care Guidelines.

### Children's Oncology Group Contact

Gladys Silva

Administrative Coordinator

Study Development Office

Children's Oncology Group

Phone: (626) 241-1574

Fax: (626) 447-4293

Email: [gsilva@childrensoncologygroup.org](mailto:gsilva@childrensoncologygroup.org)

## Supportive Care Guidelines

The following guidelines are provided for institutional consideration. Investigator discretion should be used and institutional considerations made for specific patient situations. Study Chairs should be notified of any Serious Adverse Events, an investigator's decision to deviate in a major way from protocol-directed therapy, or a patient taken off study. All such actions should be documented in the medical record and the case report forms.

Aggressive supportive care improves outcome, particularly in high-risk patient populations. The following guidelines are intended to give general direction for optimal patient care and to encourage uniformity in the treatment of patients on COG studies. Additional supportive care guidance may also be found in:

Altman, AJ, ed. *Supportive Care of Children with Cancer*. 3<sup>rd</sup> ed. Baltimore, MD: The Johns Hopkins University Press; 2004.

### DIARRHEA

Diarrhea may be a result of damage to the cellular lining of the GI tract secondary to the administration of antineoplastic agents. Anti-metabolites, especially fluorouracil, and agents such as irinotecan, hematopoietic stem cell transplant, and abdominal or pelvic irradiation are most commonly associated with diarrhea.<sup>2</sup> Uncontrolled diarrhea can lead to serious fluid and electrolyte imbalances, contribute to the child's nutritional deficits and feelings of fatigue, and cause perianal skin breakdown.

#### General measures:

Avoid fatty, greasy foods, and limit intake of dairy products or consider the use of lactase or low-lactose milk products. Consume easy to digest carbohydrates such as rice, white bread and potatoes. Drink fluids frequently between meals to avoid dehydration (Gatorade®, bouillon, apple juice, gelatin, and grape juice). Avoid caffeinated drinks including soft drinks.

To prevent perianal skin breakdown clean the perianal area with mild soap and warm water after each loose bowel movement. Dry skin thoroughly and allow exposure to air as much as possible. Apply barrier cream such as A&D ointment or a zinc oxide containing ointments to dried area.

#### Diarrhea associated with Hematopoietic Stem Cell Transplant:

Apply general measures above and consider evaluation for infection (e.g.: clostridium difficile, CMV, cryptosporidium, etc.) and GI GVHD.

#### Diarrhea Secondary to Irinotecan

Patients who have the onset of diarrhea during the irinotecan infusion or in the several hours following completion of the irinotecan infusion should receive a dose of atropine (suggested dose 0.01 mg/kg IV, maximum dose 0.4 mg). Each family should be instructed to have antidiarrheal medication available and begin treatment at the first episode of poorly formed or loose stools or the earliest onset of bowel movements more frequent than normally expected for the patient. Patients should also be instructed to contact their physician if any diarrhea occurs.

Loperamide dosing recommendations for late diarrhea which occurs 8 hours after irinotecan (based on body weight):

Under 13 kg: Take 0.5 mg after the first loose bowel movement, followed by 0.5 mg every 3 hours. During the night, the patient may take 0.5 mg every 4 hours. Do not exceed 4 mg per day.

From 13 kg to less than 20 kg: Take 1 mg after the first loose bowel movement, followed by 1 mg every 4 hours. Do not exceed 6 mg per day.

From 20 kg to less than 30 kg: Take 2 mg after the first loose bowel movement, followed by 1 mg every 3 hours. During the night, the patient may take 2 mg every 4 hours. Do not exceed 8 mg per day.

From 30 kg to less than 43 kg: Take 2 mg after the first loose bowel movement, followed by 1 mg every 2 hours. During the night, the patient may take 2 mg every 4 hours. Do not exceed 12 mg per day.

->12 years old and adults: Take 4 mg after the first loose bowel movement, followed by 2 mg after each loose stool. Do not exceed 16 mg per day.

High dose loperamide (adults) 2mg every 2 hours

Failure of loperamide to control diarrhea within 24 hours of onset:

Begin subcutaneously or intravenously administered octreotide (Sandostatin®), 1-2 mcg/kg/dose every 12 hours. If needed, the dose may be titrated up to 10 mcg/kg/dose (maximum dose: 500 mcg) every 8 hours.

***Antibiotics for GI Toxicities***

For patients who develop Grade 3 or 4 gastrointestinal (GI) toxicity (see table below for the indications for antibiotic use) following irinotecan therapy, administration guidelines are provided for cefpodoxime (Vantin®) and cefixime (Suprax®).

**Cefpodoxime:** 10 mg/kg/day, divided in 2 oral doses; maximum daily dose 400 mg for children < 12 years and maximum daily dose 800 mg for those ≥ 12 years)

**or**

**Cefixime:** (8 mg/kg/dose as a single daily oral dose or divided BID; maximum daily dose 400 mg).

The antibiotic should be started 5 days prior to the start of irinotecan therapy only if the patient experienced Grade 3 or 4 colitis, dehydration, diarrhea, abdominal pain, weight loss or vomiting during prior therapy with irinotecan. If it is not feasible to start cefpodoxime or cefixime 5 days prior to therapy with irinotecan, give at least 1 full day of cefpodoxime or cefixime prior to the start of irinotecan course. Refer to institutional guidelines for administration.

### Indications for Antibiotic Use (Cefpodoxime or Cefixime) for GI Toxicities Due to Irinotecan

| Toxicity                      | Defined as   |
|-------------------------------|--|
| <b>Abdominal Pain</b>         | Severe pain, pain or analgesics severely interfering with activities of daily living, disabling.   |
| <b>Colitis (Grade 3 or 4)</b> | Abdominal pain, fever, change in bowel habits with ileus or peritoneal signs, and radiographic or biopsy documentation of perforation or requiring surgery or toxic megacolon.   |
| <b>Dehydration</b>            | Requiring IV fluid replacement (sustained), physiologic consequences requiring intensive care, hemodynamic collapse.   |
| <b>Diarrhea</b>               | Increase of $\geq 7$ stools/day or incontinence; or need for parenteral support for dehydration, severe increase in loose stool, physiologic consequences requiring intensive care, hemodynamic collapse, <u>or</u> watery stool output compared with pretreatment, interfering with normal activity, physiologic consequences requiring intensive care, hemodynamic collapse. |
| <b>Vomiting</b>               | $\geq 6$ episodes in 24 hours over pretreatment, or need for IV fluids requiring parenteral nutrition, or physiologic consequences requiring intensive care, hemodynamic collapse.   |
| <b>Weight Loss</b>            | $> 20\%$   |

Adapted from<sup>7</sup> Perry MC et al., ed. *Companion Handbook to Chemotherapy Source Book*. 2<sup>nd</sup> ed. Baltimore, MD: Lippinkott, Williams and Wilkins; 2004.